ImmBio Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 6

ImmBio General Information

Description

Developer of vaccines designed to offer treatment for infectious diseases and cancer. The company's vaccines treat bacterial infections and mimic normal immune responses to pathogens utilizing multi-protein complexes to elicit priming of the immune system, enabling healthcare providers to directly induce immunity via dendritic cells.

Contact Information

Website
www.immbio.net
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Babraham Research Campus
  • Babraham
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Babraham Research Campus
  • Babraham
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Secondary Transaction - Private Completed Clinical Trials - Phase 1
9. Later Stage VC 18-Mar-2016 Completed Clinical Trials - Phase 1
8. Grant 28-Mar-2013 Completed Generating Revenue
7. Later Stage VC 18-Oct-2012 Completed Generating Revenue
6. Later Stage VC (Series C) 18-Sep-2007 Completed Generating Revenue
5. Grant 05-Nov-2006 Completed Generating Revenue
4. Later Stage VC (Series C) 22-Jan-2006 Completed Generating Revenue
3. Early Stage VC 12-Nov-2003 Completed Startup
2. Early Stage VC 01-Jun-2001 $642K Completed Startup
1. Seed Round 07-Dec-2000 $642K $642K Completed Startup
To view ImmBio’s complete valuation and funding history, request access »

ImmBio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
E Ordinary
D Ordinary
C Preferred 1,240,641 $0.141783 $1.93 $1.93 1x $1.93 1.13%
C Ordinary 16,043 $0.141783 $1.93 $1.93 1x $1.93 0.01%
To view ImmBio’s complete cap table history, request access »

ImmBio Patents

  • 78

    Total Documents Applications and Grants

  • Total Patents Families

  • 29

    Granted

  • Pending

  • Expiring in next 12 mo

ImmBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201611084-D0 Vaccine compositions Inactive 24-Jun-2016
US-10669563-B2 Method for the production of protein complexes and vaccine compositions comprising the same Active 23-Mar-2011
GB-201104897-D0 Method for the production of protein complexes and vaccine compositions comprising the same Inactive 23-Mar-2011
AU-2012232878-A1 Method for the production of protein complexes and vaccine compositions comprising the same Inactive 23-Mar-2011
AU-2017203173-B2 Method for the production of protein complexes and vaccine compositions comprising the same Inactive 23-Mar-2011 C12P21/00
To view ImmBio’s complete patent history, request access »

ImmBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmBio Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Biomedical Catalyst Government
Hygea Health Holdings Holding Company Minority
East of England Development Agency Corporation
Inventages Corporate Venture Capital Minority
Interikea Finance Other Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

ImmBio FAQs

  • When was ImmBio founded?

    ImmBio was founded in 1999.

  • Where is ImmBio headquartered?

    ImmBio is headquartered in Cambridge, United Kingdom.

  • What is the size of ImmBio?

    ImmBio has 5 total employees.

  • What industry is ImmBio in?

    ImmBio’s primary industry is Drug Discovery.

  • Is ImmBio a private or public company?

    ImmBio is a Private company.

  • What is ImmBio’s current revenue?

    The current revenue for ImmBio is .

  • How much funding has ImmBio raised over time?

    ImmBio has raised $20.1M.

  • Who are ImmBio’s investors?

    Biomedical Catalyst, Hygea Health Holdings, East of England Development Agency, Inventages, and Interikea Finance are 5 of 6 investors who have invested in ImmBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »